| Term 
 | Definition 
 
        | DOC for >65 y Parkinson's Side Effects:  Dyskinesias, On-off motor MOA: inhibits decarboxylation of peripheral levodopa. In presence of Carbidopa, crosses blood-brain barrier, is carboxylated into dopamine |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | <65 y Parkinson's Side Effects: Confusion, ankle swelling MOA:  dopamine released from remaining intact dopaminergic terminals in substantia nigra |  | 
        |  | 
        
        | Term 
 
        | Pramipexole or Ropinarole |  | Definition 
 
        | <65 monotherapy Parkinson's; advanced pt adjunct to L-dopa Side Effects: postural hypotension, hallucination, drowsiness (esp elderly) MOA:  directly stimulate dopamine receptors |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Parkinson's, adjunct to L-dopa Side Effects:  GI, dyskinesias MOA:  inhibit plasma COMT(catechol-O methyl tranferase) enzyme--> prolongs T 1/2 of Levodopa. |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | adjunct to L-dopa Side Effects: GI, dyskinesias, elevation of liver enzymes (seldome used, must monitor serial LFT's)   MOA:  COMT inhibitor |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | young, mild Parkinson's:  tremor, drooling Side Effects:  anticholinergic S/E=dry mouth, cognitive changes MOA: antimuscarinic (prevents drooling) |  | 
        |  | 
        
        | Term 
 
        | Opioids (see 4/10 Medical Letter) morphine, codeine, hydrocodone, oxycodone, heroin |  | Definition 
 
        | moderate to severe pain; postoperative med; adjunct for  anaesthesia; some have antussive, antidiarrheal effects AVOID in case of ill-defined chronic pain.   Side effects: addiction, constipation; overdose: coma, respiratory depression, miosis ("pinpoint pupils"); hypotension, decreased bowel sounds (acute: nausea and vomiting)   MOA:  agonists at mu, delta, and kappa opioid receptors; primarily through Gi/Go proteins to hyperpolarize neurons and inhibit neurotransmitter release.   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | opiod overdose side effects: severe withdrawal if physically dependent MOA: opioid antagonist |  | 
        |  | 
        
        | Term 
 
        | fentanyl (also meperidine, propoxyphene, tramadol, methadone, remifentanil) |  | Definition 
 
        | synthetic opioid agonist fentanyl patch:  for systemic pain, slow release   Side Effects:  meperidine--excessive doses can lead to seizures from excessive accumulation of metabolites (esp if renal function impaired) |  | 
        |  | 
        
        | Term 
 
        | buprenorphine, nalbuphine |  | Definition 
 
        | partial agonist or mixed agonist/antagonist |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | to reverse respiratory and CNS depression in suspected overdose MOA:  displaces opioid narcotics from receptor sites |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | for opioid addiction and alcoholism (binge drinking, bulimia) MOA:  longer acting bioavailable opioid antagonist |  | 
        |  | 
        
        | Term 
 
        | diphenoxylate, loperamide |  | Definition 
 
        | antidiarrheal agent MOA: opioid-related |  | 
        |  | 
        
        | Term 
 
        | lidocaine, procaine, bupivicaine, cocaine (ENT): need DURATION OF ACTION |  | Definition 
 
        | local anaesthesia (dental extraction, suturing), spinal anesthesia, nerve blocks   MOA:  block sodium channels, which prevents generation and conduction of nerve impulses Combo with vasoconstrictors:  epinephrine, phenylephrine, prolongs duration of action   Lidocaine: widely used, infiltration, prolonged by vasoconstrictors Procaine: action is transient, allergic response likely (PABA) Bupivicaine: injectable, long duration (binds to plasma proteins) Cocaine: naturally occuring from Eythroxylon coca--can cause CNS depression and death (respiratory) following use.  Blocks uptake of catecholamines |  | 
        |  | 
        
        | Term 
 
        | Guidelines for Epilepsy (AOA competencies) |  | Definition 
 
        | 1) Know which drugs for which type of seizure (ex: phenytoin makes absence seizures worse) 2) Medical Letter: phenytoin no longer DOC for tonic-clonic or partial seizures 3) Treatment of epilepsy should begin with single drug 4) Difficult to control patients should be seen by a neurologist   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | DOC for generalized TONIC-CLONIC (Grand Mal) seizure (mood stabilization effect) DOC for ABSENCE (Petit Mal) seizure   Side Effects:  nausea/vomiting common (depakote enteric coated=better, also take with food, slow titration); weight gain relatively common; serious effects--uncommon--unexplained heptatoxicity esp <2 y (monitor liver function tests)   MOA: may increase GABA in brain. |  | 
        |  | 
        
        | Term 
 
        | lamotrigine (synergy? with valproate) |  | Definition 
 
        | DOC for generalized TONIC-CLONIC (Grand Mal) DOC for ATYPICAL ABSENCE, MYOCLONIC, ATONIC some adults: monotherapy children >2 and adults: adjunct for partial seizures   Side Effects:  rash (Stevens-Johnsons' Syndrome: severe, diffuse, involvment of mucosal surfaces).  Risk of rash high if hi dose, dose increased too fast, or given w/ valproate.  discontinue at first appearance of rash.   MOA: ?     |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | DOC for TONIC-CLONIC (Grand Mal) DOC for PARTIAL, including secondary generalized seizures DOC for ATYPICAL ABSENCE, MYOCLONIC, ATONIC   adults and children >4 y w/ partial seizures adults and children > 6 y w/ primary generalized seizures--TONIC CLONIC adults and children > 12 y w/ myoclonic seizures   Side Effects:  somnolence, dizziness, weakness, irritability but not life-threatening. Few drug-drug interactions (not metabolized by CP450)   MOA:  selective binding to synaptic vesicular protein SV2A (may modify synaptic release of glutamate, GABA)   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | DOC for PARTIAL, including some secondary generalized seizures   Side Effects:  rashes w/ high doses (Stephen Johnson).  Asians at risk for severe skin rashes (test for HLA-B1502 in advance) CNS (drowsiness, headache, decreased cognitive function) mild leukopenia, hyponatremia many drug-drug interactions   MOA:  may reduce polysynaptic responses and block post-tetanic potentiation.  Treat chronic pain of trigeminal neuralgia and diabetic neuropathy. |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | DOC for PARTIAL, including secondary generalized seizures may WORSEN some patients with ABSENCE absence   Side Effects:  Rashes, esp w/ hi doses, Asians at risk for severe skin rashes (test for HLA-B1502 in advance).  CNS (drowsiness, headache, decreased cognitive function)   MOA:  reduces polysynaptic responses and blocking post-tetanic potentiation.  Also used to treat chronic pain of trigeminal neuralgia and diabetic neuropathy |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | DOC for ABSENCE (Petit Mal)   Side Effects:  well tolerated (nausea, vomiting, hiccups)   MOA: ?   |  | 
        |  | 
        
        | Term 
 
        | pheytoin (formerly dipheylhydantoin) |  | Definition 
 
        | second-line drug, previously DOC for generalized tonic-clonic and partial seizures   Side Effects:  complicated pharmacokinetics.  Nystagmus, drowsiness, ataxia, diplopia, rash/hypersensitivity, gingival hyperplasia   MOA:  may block sodium channels (stabilize threshold against hyperexcitability).  Blocks calcium channels.  May enhance GABA. |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | combination Rx, chronic pain syndromes   Side effects:  few drug-drug interactions |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | adjunctive theapy for variety of seizures phophylactic for migraines treatment for neuropathic pain   Side Effects:  paresthesisas, cognitive impairment; chronic use may cause metabolic acidosis, increasing risk of renal calculi   MOA:  carbonic anhydrase inhibitor |  | 
        |  | 
        
        | Term 
 
        | diazepam (see benzodiazepines) single-dose prefilled syringes   Diastat:  new rectal formulation |  | Definition 
 
        | repetitive seizures (rapidly absorbed, effective for acute seizures, can be used in combo with other antiepileptics) may decrease ER visits   Side Effects:  ? make seizures worse   MOA:     |  | 
        |  | 
        
        | Term 
 
        | ginkgo biloba (see herbals) |  | Definition 
 
        | Natural Standard A grade for dementia B grade for cerebral insufficiency   Side Effects:  bleeding as montherapy, in combo   MOA: |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |  B for improving mental performance   Side Effects:  bleeding as monotherapy and combo, care when combo with cardiac drugs     |  | 
        |  |